Drug intelligence / Profile preview

OsteoAdapt

Development stage: Unknown
Lead developer: Theradaptive
Modality: Recombinant Proteins and Enzymes
Administration: Implantation, Local Administration

Overview

OsteoAdapt is a regenerative therapeutic developed by Theradaptive, a biopharmaceutical company. It is designed for tissue repair, specifically targeting spine and trauma repair, as well as localized alveolar ridge augmentations. The therapeutic is based on Theradaptive's protein-engineering platform, AMP2, which aims to create targeted therapeutics. It is being developed for first-in-human clinical trials and is classified as a medical device in some clinical contexts, suggesting it may be a combination product.

Targets

ACVR1 (Activin receptor type I)

Beyond the preview

Go deeper on OsteoAdapt.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OsteoAdapt.

Explore the full profile